Xian-Zhi Li

Dr. Xian-Zhi Li

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
XLXian-Zhi Li
Xian-Zhi Li
PPPatrick Plésiat
Patrick Plésiat
HNHiroshi Nikaido
Hiroshi Nikaido
SUMMARY The global emergence of multidrug-resistant Gram-negative bacteria is a growing threat to antibiotic therapy. The chromosomally encoded drug efflux mechanisms that are ubiquitous in these bacteria greatly contribute to antibiotic resistance and present a major challenge for antibiotic development. Multidrug pumps, particularly those represented by the clinically relevant AcrAB-TolC and Mex pumps of the resistance-nodulation-division (RND) superfamily, not only mediate intrinsic and acquired multidrug resistance (MDR) but also are involved in other functions, including the bacterial stress response and pathogenicity. Additionally, efflux pumps interact synergistically with other resistance mechanisms (e.g., with the outer membrane permeability barrier) to increase resistance levels. Since the discovery of RND pumps in the early 1990s, remarkable scientific and technological advances have allowed for an in-depth understanding of the structural and biochemical basis, substrate profiles, molecular regulation, and inhibition of MDR pumps. However, the development of clinically useful efflux pump inhibitors and/or new antibiotics that can bypass pump effects continues to be a challenge. Plasmid-borne efflux pump genes (including those for RND pumps) have increasingly been identified. This article highlights the recent progress obtained for organisms of clinical significance, together with methodological considerations for the characterization of MDR pumps.

6 November 2023 in One Health Advances
Verified
Journal Article
Open access
PDF file
AFAndrea T. Feßler
Andrea T. Feßler
YWYang Wang
Yang Wang
CBClaire R. Burbick
Claire R. Burbick
DDDubraska Diaz-Campos
Dubraska Diaz-Campos
VFVirginia R. Fajt
Virginia R. Fajt
Stefan SchwarzStefan Schwarz
Stefan Schwarz
The performance of antimicrobial susceptibility testing (AST) of bacteria and the interpretation of AST results for bacteria isolated from animals are complex tasks which must be performed using standard published methodology and overseen by experts in clinical microbiology and in consultation with clinical pharmacologists. Otherwise, AST has significant potential for errors and mistakes. In this review, we provide guidance on how to correctly perform AST of bacteria isolated from animals and interpret the AST results. Particular emphasis is placed on the various approved or published methodologies for the different bacteria as well as the application of interpretive criteria, including clinical breakpoints and epidemiological cut-off values (ECVs/ECOFFs). Application of approved interpretive criteria and definitions of susceptible, susceptible dose-dependent, nonsusceptible, intermediate, and resistant for clinical breakpoints as well as wild-type and non-wildtype for ECVs, are explained and the difficulties resulting from the lack of approved clinical breakpoints for other bacteria, indications, and animal species is discussed. The requirement of quality controls in any AST approach is also emphasized. In addition, important parameters, often used in monitoring and surveillance studies, such as MIC50, MIC90, and testing range, are explained and criteria for the classification of bacteria as multidrug-resistant, extensively drug-resistant or pandrug-resistant are provided. Common mistakes are presented and the means to avoid them are described. To provide the most accurate AST, one must strictly adhere to approved standards or validated methodologies, like those of the Clinical and Laboratory Standards Institute or other internationally accepted AST documents and the detailed information provided therein.

4 November 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
CCCarolee Carson
Carolee Carson
XLXian-Zhi Li
Xian-Zhi Li
AAAgnes Agunos
Agnes Agunos
DLDaleen Loest
Daleen Loest
BCBrennan Chapman
Brennan Chapman
RIRebecca Irwin
Rebecca Irwin
Codex published the ‘Guidelines for Risk Analysis of Foodborne Antimicrobial Resistance’ to standardise the approach for evaluating risk posed by foodborne antimicrobial-resistant bacteria. One of the first steps in the guidelines is to compile a risk profile, which provides the current state of knowledge regarding a food safety issue, describes risk management options and recommends next steps. In Canada, ceftiofur/ceftriaxone-resistant Salmonella enterica subsp. enterica serovar Heidelberg from poultry was identified as an antimicrobial resistance (AMR) food safety issue. The first objective of this article was to contextualise this food safety issue, using the risk profile format of the Codex Guidelines. A second objective was to evaluate the applicability of the Codex Guidelines. This risk profile indicated that ceftiofur/ceftriaxone-resistant S. Heidelberg (CSH) was commonly isolated from poultry and was associated with severe disease in humans. Ceftiofur use in poultry hatcheries temporally mirrored the prevalence of CSH from poultry meat at retail and from people with salmonellosis. The evidence was sufficient to indicate the need for risk management options, such as restricting the use of ceftiofur in poultry. The Codex Guidelines provided a useful approach to summarise data for decision-makers to evaluate an AMR food safety issue.

29 June 2022 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
DLDaleen Loest
Daleen Loest
FUFrederick Carl Uhland
Frederick Carl Uhland
KYKaitlin M. Young
Kaitlin M. Young
XLXian-Zhi Li
Xian-Zhi Li
MMMichael R. Mulvey
Michael R. Mulvey
CCCarolee A. Carson
Carolee A. Carson
Resistance to carbapenems in human pathogens is a growing clinical and public health concern. The carbapenems are in an antimicrobial class considered last-resort, they are used to treat human infections caused by multidrug-resistant Enterobacterales, and they are classified by the World Health Organization as ‘High Priority Critically Important Antimicrobials’. The presence of carbapenem-resistant Enterobacterales (CREs) of animal-origin is of concern because targeted studies of Canadian retail seafood revealed the presence of carbapenem resistance in a small number of Enterobacterales isolates. To further investigate this issue, a risk profile was developed examining shrimp and salmon, the two most important seafood commodities consumed by Canadians and Escherichia coli, a member of the Enterobacterales order. Carbapenem-resistant E. coli (CREc) isolates have been identified in shrimp and other seafood products. Although carbapenem use in aquaculture has not been reported, several classes of antimicrobials are utilised globally and co-selection of antimicrobial-resistant microorganisms in an aquaculture setting is also of concern. CREs have been identified in retail seafood purchased in Canada and are currently thought to be uncommon. However, data concerning CRE or CREc occurrence and distribution in seafood are limited, and argue for implementation of ongoing or periodic surveillance.

10 November 2016
Verified
Book Chapter
Closed access
PDF file
XLXian-Zhi Li
Xian-Zhi Li
PPPatrick Plésiat
Patrick Plésiat